Early Alzheimer's data sound good, but Biogen has much to prove
This article was originally published in Scrip
Could Biogen Idec have a successful treatment for Alzheimer's disease in a class of drugs where others have failed before? Maybe, but the company will have a lot to prove as it "very aggressively" pursues Phase III development following what appear to be promising Phase Ib results for BIIB037.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.